• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Jaguar Health Inc.

    12/11/25 4:49:34 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAGX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Jaguar Health, Inc.

    (Name of Issuer)


    Common Stock, Par Value $0.0001 Per Share

    (Title of Class of Securities)


    47010C888

    (CUSIP Number)


    12/11/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    47010C888


    1Names of Reporting Persons

    Iliad Research & Trading, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UTAH
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    440,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    440,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    440,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  * Based on 4,497,108 shares outstanding as of December 10, 2025.


    SCHEDULE 13G

    CUSIP No.
    47010C888


    1Names of Reporting Persons

    Iliad Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    440,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    440,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    440,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  * Based on 4,497,108 shares outstanding as of December 10, 2025.


    SCHEDULE 13G

    CUSIP No.
    47010C888


    1Names of Reporting Persons

    Fife Trading, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ILLINOIS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    440,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    440,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    440,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  * Based on 4,497,108 shares outstanding as of December 10, 2025.


    SCHEDULE 13G

    CUSIP No.
    47010C888


    1Names of Reporting Persons

    John M. Fife
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    440,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    440,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    440,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  * Based on 4,497,108 shares outstanding as of December 10, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Jaguar Health, Inc.
    (b)Address of issuer's principal executive offices:

    200 PINE STREET SUITE 400, SAN FRANCISCO, CALIFORNIA, 94104
    Item 2. 
    (a)Name of person filing:

    This report is filed by Iliad Research and Trading, LP, Iliad Management, LLC, Fife Trading, Inc., and John M. Fife with respect to the shares of Common Stock, $0.0001 par value per share, of the Issuer that are directly beneficially owned by Iliad Research and Trading, LP and indirectly beneficially owned by the other reporting and filing persons.
    (b)Address or principal business office or, if none, residence:

    300 East Randolph Street, Suite 40.150, Chicago, IL 60601
    (c)Citizenship:

    Iliad Research and Trading, LP is a Utah limited partnership. Iliad Management, LLC is a Delaware limited liability company. Fife Trading, Inc. is an Illinois corporation. John M. Fife is a United States citizen.
    (d)Title of class of securities:

    Common Stock, Par Value $0.0001 Per Share
    (e)CUSIP No.:

    47010C888
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    440,000
    (b)Percent of class:

    9.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    440,000

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    440,000

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Iliad Research & Trading, L.P.
     
    Signature:John Fife
    Name/Title:President
    Date:12/11/2025
     
    Iliad Management, LLC
     
    Signature:John Fife
    Name/Title:President
    Date:12/11/2025
     
    Fife Trading, Inc.
     
    Signature:John Fife
    Name/Title:President
    Date:12/11/2025
     
    John M. Fife
     
    Signature:John Fife
    Name/Title:John Fife
    Date:12/11/2025
    Get the next $JAGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAGX

    DatePrice TargetRatingAnalyst
    7/7/2021$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $JAGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Lincoln Alternative Strategies Llc claimed ownership of 600,000 shares (SEC Form 3)

    3 - Jaguar Health, Inc. (0001585608) (Issuer)

    8/29/25 4:05:28 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Siegel Jonathan B.

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    6/26/25 4:42:04 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Micek John

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    6/26/25 4:40:04 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $JAGX
    SEC Filings

    View All

    $JAGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream

    MIAMI, Dec. 10, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Presenting Day 1 – Today - December 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already regis

    12/10/25 7:00:00 AM ET
    $AEM
    $CIA
    $CLNN
    Precious Metals
    Basic Materials
    Life Insurance
    Finance

    Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream

    MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayDecember 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go

    12/9/25 7:00:00 AM ET
    $AEM
    $CIA
    $CLNN
    Precious Metals
    Basic Materials
    Life Insurance
    Finance

    Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

    MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – TodaySeptember 24, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go b

    9/24/25 7:00:00 AM ET
    $ADVM
    $AIIO
    $BANL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Auto Manufacturing
    Industrials

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    12/12/25 4:46:54 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Jaguar Health Inc.

    SCHEDULE 13G - Jaguar Health, Inc. (0001585608) (Subject)

    12/11/25 4:49:34 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    12/8/25 4:30:27 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Jaguar Health with a new price target

    Cantor Fitzgerald initiated coverage of Jaguar Health with a rating of Overweight and set a new price target of $5.00

    7/7/21 6:37:12 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Leadership Updates

    Live Leadership Updates

    View All

    Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

    FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals."Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We ar

    9/10/24 10:00:00 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

    Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy."Cathy Collis was instrumental in bringing about the Gelclair in-license agreement. She is a results-oriented commercial leader with more than 25 years of experience in the biopharmaceutical industry, and

    4/18/24 8:30:00 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

    Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S.Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium priceSAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr

    4/2/24 8:30:00 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Financials

    Live finance-specific insights

    View All

    Jaguar Health Reports 2020 Financial Results and Business Updates

    Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year. In 2020, the Company's animal product research and development efforts were intentionally minimal, and Jaguar's animal-related sales were also minimal.

    3/31/21 4:15:00 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jaguar Health Inc.

    SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)

    7/22/24 4:10:52 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jaguar Health Inc. (Amendment)

    SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)

    6/10/24 11:26:28 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Jaguar Health Inc.

    SC 13G - Jaguar Health, Inc. (0001585608) (Subject)

    12/29/23 11:09:37 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care